How effective are TNF inhibitors in axial spondyloarthritis?

Study of more than 24,000 registry patients shows real-world efficacy and adherence
Clare Pain
Anklyosing spondylitis X-ray of spine

About one in three patients with axial spondyloarthritis are likely to achieve inactive disease six months into therapy with a TNF inhibitor, a large registry study suggests.

The real-world analysis of patients naïve to biologics showed that 33% achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) of below 1.3 at six months.